Targeted Therapies in the Fight Against Cancer

Actinium is a leading biotechnology company developing targeted radioimmunotherapies for the treatment of cancer patients with unmet needs.

About Actinium

Bone Marrow Transplant Induction and Conditioning in One

Iomab-B, Actinium’s lead asset, is in a pivotal Phase 3 clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT. View highlights of Key Opinion Leaders discussing Iomab-B:

View Clinical Panel Discussion

Highly Specific Target and Antileukemic Effect

Actinium’s Actimab-A drug candidate targets CD33, which is expressed in a majority of patients with AML. Actimab-A is in a Phase 2 Clinical Trial for newly diagnosed Acute Myeloid Leukemia (AML) patients over the age of 60. Results from previous studies suggest Actimab-A may have a clear antileukemic effect.

View Actimab-A

World Class Science

Actinium’s Technology platform couples monoclonal antibodies with extremely potent radioisotopes, to create innovative approaches to radioimmunotherapy drug development.

About Actinium Technology

Robust Pipeline

Actinium Pharmaceuticals' drug development pipeline features Iomab-B, which is in a pivotal Phase 3 clinical trial and Actimab-A, which is in a Phase 2 clinical trial Actimab-M in a Phase 1 clinical trial. Actinium is focused on continuing to expand its drug development pipeline by leveraging its APIT technology platform and domain expertise.

View Pipeline

Email Sign Up

Receive the latest news, events and updates!

Sign Up Now